RAFAEL HOLDINGS, INC. Restricted Cash and Cash Equivalents
RAFAEL HOLDINGS, INC. (RFL) had Restricted Cash and Cash Equivalents of $13.20 million as of 2023-10-31, per its 10-Q filed 2023-12-14.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-12-14
- 2023-10-31: Restricted Cash and Cash Equivalents $13.20M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-10-31 | $13.20M 10-Q · filed 2023-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |